Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313366107> ?p ?o ?g. }
Showing items 1 to 76 of
76
with 100 items per page.
- W4313366107 endingPage "136.12" @default.
- W4313366107 startingPage "136.12" @default.
- W4313366107 abstract "Abstract Background Melanoma is one of the deadliest forms of skin cancer, and its incidence has continued to rise during the past decade. Isorhapontigenin (ISO) is a new derivative of stilbene compound, isolated from Chinese herb Gnetum Cleistostachyum with capability of antitumor. Purpose The potential anti-melanoma activity, impact on genes’ expression, as well as the influence of immune response against melanoma of ISO were detected in our studies in order to clarify its anti-melanoma effect and the corresponding mechanism. Methods Cytotoxicity of ISO on melanoma cell line B16F10 was studied by performing 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT). Cell cycle analysis by flow cytometry, annexin V staining, RT-qPCR and Western blot were used to elucidate the mechanism of action of ISO at the cellular level. The in vivo anti-tumor ability of ISO was measured in C57BL/6 mouse syngraft models. Results ISO induced dose-dependent inhibitory effect on the proliferation of B16F10 cell by arresting cells at G0/G1 phase promoting the apoptosis of the cell, which was associated with an increase in the Bax:Bcl-2 ratio and decrease in the proliferative-related genes CYCLIN D1 and SURVIVIN in vitro. In addition, ISO could inhibit the tumor immune escape by promoting the expression of MHC molecules on the membrane of tumor cells, and decreased the infiltration of Tregs and MDSCs which involved in suppressing the anti-tumor effects of immune system. On the other hand, ISO increased the infiltration of T cells, NK cells and NKT cells, which was able to enhance the anti-tumor immune response. Conclusion Taken together, these findings indicate that ISO may be useful as a treatment for Melanoma and thus warrants further investigation." @default.
- W4313366107 created "2023-01-06" @default.
- W4313366107 creator A5004761026 @default.
- W4313366107 creator A5010726080 @default.
- W4313366107 creator A5019112889 @default.
- W4313366107 creator A5028169886 @default.
- W4313366107 creator A5031771327 @default.
- W4313366107 creator A5046023135 @default.
- W4313366107 creator A5084229227 @default.
- W4313366107 date "2019-05-01" @default.
- W4313366107 modified "2023-09-27" @default.
- W4313366107 title "Isorhapontigenin shows strong anti-melanoma cell activity, and induces anti-tumor immunity" @default.
- W4313366107 doi "https://doi.org/10.4049/jimmunol.202.supp.136.12" @default.
- W4313366107 hasPublicationYear "2019" @default.
- W4313366107 type Work @default.
- W4313366107 citedByCount "0" @default.
- W4313366107 crossrefType "journal-article" @default.
- W4313366107 hasAuthorship W4313366107A5004761026 @default.
- W4313366107 hasAuthorship W4313366107A5010726080 @default.
- W4313366107 hasAuthorship W4313366107A5019112889 @default.
- W4313366107 hasAuthorship W4313366107A5028169886 @default.
- W4313366107 hasAuthorship W4313366107A5031771327 @default.
- W4313366107 hasAuthorship W4313366107A5046023135 @default.
- W4313366107 hasAuthorship W4313366107A5084229227 @default.
- W4313366107 hasConcept C109316439 @default.
- W4313366107 hasConcept C153911025 @default.
- W4313366107 hasConcept C185592680 @default.
- W4313366107 hasConcept C190283241 @default.
- W4313366107 hasConcept C202751555 @default.
- W4313366107 hasConcept C203014093 @default.
- W4313366107 hasConcept C2775975398 @default.
- W4313366107 hasConcept C2777658100 @default.
- W4313366107 hasConcept C29537977 @default.
- W4313366107 hasConcept C502942594 @default.
- W4313366107 hasConcept C553184892 @default.
- W4313366107 hasConcept C55493867 @default.
- W4313366107 hasConcept C62112901 @default.
- W4313366107 hasConcept C86803240 @default.
- W4313366107 hasConcept C88634738 @default.
- W4313366107 hasConcept C8891405 @default.
- W4313366107 hasConceptScore W4313366107C109316439 @default.
- W4313366107 hasConceptScore W4313366107C153911025 @default.
- W4313366107 hasConceptScore W4313366107C185592680 @default.
- W4313366107 hasConceptScore W4313366107C190283241 @default.
- W4313366107 hasConceptScore W4313366107C202751555 @default.
- W4313366107 hasConceptScore W4313366107C203014093 @default.
- W4313366107 hasConceptScore W4313366107C2775975398 @default.
- W4313366107 hasConceptScore W4313366107C2777658100 @default.
- W4313366107 hasConceptScore W4313366107C29537977 @default.
- W4313366107 hasConceptScore W4313366107C502942594 @default.
- W4313366107 hasConceptScore W4313366107C553184892 @default.
- W4313366107 hasConceptScore W4313366107C55493867 @default.
- W4313366107 hasConceptScore W4313366107C62112901 @default.
- W4313366107 hasConceptScore W4313366107C86803240 @default.
- W4313366107 hasConceptScore W4313366107C88634738 @default.
- W4313366107 hasConceptScore W4313366107C8891405 @default.
- W4313366107 hasIssue "1_Supplement" @default.
- W4313366107 hasLocation W43133661071 @default.
- W4313366107 hasOpenAccess W4313366107 @default.
- W4313366107 hasPrimaryLocation W43133661071 @default.
- W4313366107 hasRelatedWork W1477537279 @default.
- W4313366107 hasRelatedWork W2185175380 @default.
- W4313366107 hasRelatedWork W2358161411 @default.
- W4313366107 hasRelatedWork W2365904970 @default.
- W4313366107 hasRelatedWork W2367667778 @default.
- W4313366107 hasRelatedWork W2374067319 @default.
- W4313366107 hasRelatedWork W2378147551 @default.
- W4313366107 hasRelatedWork W2378421503 @default.
- W4313366107 hasRelatedWork W3031159451 @default.
- W4313366107 hasRelatedWork W3032847486 @default.
- W4313366107 hasVolume "202" @default.
- W4313366107 isParatext "false" @default.
- W4313366107 isRetracted "false" @default.
- W4313366107 workType "article" @default.